- BGI Genomics Announces Pricing of Initial Public Offering
- BGI Launches the Latest Desktop Sequencer BGISEQ-50
- International Science Community Welcomes China National GeneBank Opening
- BGI and Clearbridge BioMedics Partner to Develop China CTC Liquid Biopsy Market towards Precision Medicine
- The international Sc2.0 Project is on track to build the world’s first synthetic yeast genome
- Avian-specific conserved genomic elements play important regulatory roles in the macroevolution of avian-specific features
- The Evolution of Chronic Lymphocytic Leukemia Revealed
- BGI involved in publication of the first seahorse genome in Nature
- Leading Health Organizations in Canada and China Teaming up to Accelerate Precision Medicine
- World’s largest genomic organisation to collaborate with leading Queensland researchers
- Ranomics Partners with BGI to Classify Variants of Unknown Significance
- BGI and UW collaborate on precision medicine development
- Chinese innovation : BGI’s code for success
- Prof. Huanming Yang to Receive Membership from Royal Danish Academy of Sciences and Letters
- UW, Chinese genomics group forge new partnership to advance biomedical research
- Mapping more genomes will create a healthcare 'big data revolution'
Tel: +86-755-36307212Email: email@example.com
Shenzhen, China, Toronto, ON, June 2, 2016 – BGI, global leader in genomics research and clinical applications, is actively using functional studies data provided by biotech startup, Ranomics, for gene variant classification. Ranomics’ database oﬀers experimental data about genetic Variants of Unknown Significance (VUS), providing new insights into the function of VUS in model organisms. Following the American College of Medical Genetics and Genomics (ACMG) guidelines for the interpretation of sequence variants, and in combination with its multiple gene sequencing platforms, BGI plans to leverage Ranomics’ database to classify variants of susceptibility genes in Chinese high-risk breast cancer patients.
"For mutation carriers in Chinese population, the mutation spectrum and risk of incidence may be diﬀerent from the western population. So it is necessary to analyze the mutation spectrum of Chinese patients with hereditary breast cancer, in order to develop preventive methods,” indicates Yong Hou, Deputy Director of BGI Research, “The role of pathogenic variants in breast cancer is clear, but the VUS’s function in breast cancer risk is still undefined. In order to have an eﬀective prevention and therapy for hereditary breast cancer, it is necessary to classify VUS as pathogenic or benign.”
BGI is committed to interpreting all variants in their studied population and to reclassifying any mutation that has suﬃcient new evidence. Through partnering with Ranomics, BGI plans to expand the scope of its research to cover VUS of BRCA1, TP53 and CHEK2 genes which are commonly identified in Chinese patients of high-risk breast cancer.
Toronto-based Ranomics is committed to resolving VUS in genetic testing results. Earlier this year, the company launched Ranomics RING-Domain, a database of internally conducted high-throughput functional studies of 2,000 potential mutations in BRCA1, one of the most commonly mutated genes in breast and ovarian cancers.